https://www.clinicaltrialsarena.com/news/kymera-dosing-kt621-trial/
Nov 27, 2025 - Kymera Therapeutics has commenced dosing in its BROADEN2 Phase IIb clinical trial assessing oral STAT6 degrader, KT-621, in moderate to severe AD patients.
phase iibatopic dermatitiskymerainitiatesdosing
https://www.technologynetworks.com/drug-discovery/news/kuros-completes-patient-recruitment-in-a-phase-iib-clinical-trial-with-kur211-for-diabetic-foot-ulcers-199223
Study assessing the safety and efficacy of KUR-211 expected to report in mid 2012.
patient recruitmentphase iibclinical trialkuroscompletes
https://news.gsmedtech.com/746-2/
Medical Devices Medical innovations Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study Medical Device News by Guided Solutions
phase iibbonetherapeuticstreatsfirst